Dense Breasts and Supplemental Screening: What the National Notification Rule Does and Does Not Prove

Since September 10, 2024, the FDA's MQSA final rule requires every U.S. facility to tell patients whether their breasts are dense and that dense tissue can hide cancers and raise risk. It standardizes notification. It does not prove that adding ultrasound or MRI after a dense reading reduces breast cancer deaths.

The final rule amending the Mammography Quality Standards Act has been in force nationwide since that date, and it settles one question while deliberately leaving another open. It settles what you must be told: every mammography facility in the United States now has to state, in a standardized lay summary, whether your breast tissue is "dense" or "not dense," and to explain that dense tissue can hide cancers on a mammogram while also raising breast cancer risk. What the rule does not settle is whether adding an ultrasound or MRI after a dense reading will help you live longer. It is a disclosure standard, not a verdict on supplemental screening.

What the rule actually requires

The FDA published the final rule on March 10, 2023, and set a compliance date of September 10, 2024. Radiologists have long graded density on a four-level BI-RADS scale, running from almost entirely fatty through scattered fibroglandular tissue, heterogeneously dense, and extremely dense. The rule collapses those four categories into two patient-facing buckets: the top two levels are reported as "dense," the lower two as "not dense." For patients with dense tissue, the mandated language adds one conditional sentence, that "in some people with dense tissue, other imaging tests in addition to a mammogram may help find cancers," and directs the reader to discuss it with a clinician.

Two features of that text deserve attention. The wording is fixed, so facilities cannot soften or embellish it. And it is carefully conditional. The rule says supplemental imaging "may help," names no specific test, and stops short of recommending anything. As the Journal of Breast Imaging review by Berg and colleagues describes, the standard was built to replace a patchwork of state laws with uniform notification, not to prescribe a screening pathway.

Density is a category, not a diagnosis

A notification tells you which bucket a radiologist placed you in on a given day. That assignment is more subjective than the tidy label suggests. The boundary between "scattered" and "heterogeneously dense" is a visual judgment, and the same films read by two radiologists, or by the same radiologist on two occasions, do not always land in the same category. Roughly half of screened women are classified as having dense breasts, so the notification sorts an enormous population using a threshold that is itself somewhat blurry.

Density also is not the whole risk picture. Family history, genetic variants, prior high-risk biopsies, and validated lifetime-risk models each move the needle independently. A woman with extremely dense tissue and no other risk factors and a woman with scattered density who carries a BRCA mutation are not interchangeable, even though the density notice treats density as the headline. The rule surfaces one variable. It does not compute your risk.

Detection is not the same as mortality

This is where reading the evidence carefully matters most. The strongest data behind supplemental screening are cancer detection rates, and those are genuinely favorable. The Journal of Breast Imaging review summarizes that adding ultrasound finds on the order of two to three additional cancers per 1,000 examinations, while MRI finds roughly ten to twenty per 1,000 on a first round and fewer thereafter, with contrast-enhanced mammography in a similar range. Each of these also raises false positives and benign biopsies, most heavily on the first round.

Finding more cancers is not the same as preventing more deaths. Extra detection can inflate counts through lead time, meaning a cancer found earlier without the outcome changing, and through overdiagnosis of small, indolent lesions such as some ductal carcinoma in situ that might never have threatened a life. A screening test earns its keep by shifting late-stage disease and mortality downward, not by tallying additional findings. That distinction is the crux of what the notification rule cannot prove.

Where the evidence is strongest, and where it thins

The best trial evidence comes from the DENSE study, a randomized trial published in the New England Journal of Medicine in 2019 in women with extremely dense breasts. Inviting those women to supplemental MRI roughly halved the rate of interval cancers, the cancers that surface between scheduled screens, from about 5.0 to 2.5 per 1,000. That is a real, prospective signal, and it is the reason MRI has the firmest footing of any supplemental option. Even so, an interval-cancer reduction is an intermediate outcome, a plausible step toward fewer deaths rather than a measured mortality benefit, and the finding applies specifically to the extremely dense category and to MRI, not to ultrasound or to the broader "dense" population the notification covers.

The U.S. Preventive Services Task Force reached the same boundary from the other side. In its 2024 breast cancer screening recommendation, the Task Force issued an "I" statement, concluding that current evidence is insufficient to weigh the benefits and harms of supplemental ultrasound or MRI, regardless of density, because no study reported health outcomes or progression to advanced cancer across more than a single round of screening. An "I" statement is not a recommendation against supplemental imaging. It is an honest label on a gap.

Reading your own notification

A dense-breast notice is an accurate statement of two facts, that your tissue reads as dense and that supplemental imaging might find cancers a mammogram misses. It is not evidence that supplemental imaging will help you specifically, and it is not a prescription. The reasonable next step is the one the rule itself points to: a conversation that sets density alongside your full risk profile and weighs the real tradeoff of more detection against more false alarms. This article is educational and not medical advice.